Anhedonia in Parkinson's disease: A systematic review of the literature

Movement Disorders

Volumn 26, Issue 10, 2011, Pages 1825-1834

  Assogna, Francesca ^a   Cravello, Luca ^a   Caltagirone, Carlo ^a,b   Spalletta, Gianfranco ^a  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Anhedonia; Apathy; Cognitive deficits; Depression; Motor symptoms; Nonmotor symptoms; Parkinson's disease

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; LEVODOPA; PRAMIPEXOLE; ROPINIROLE;

ADD ON THERAPY; ANHEDONIA; ANXIETY DISORDER; APATHY; BRAIN FUNCTION; COGNITIVE DEFECT; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; FRONTAL LOBE; HUMAN; MAJOR DEPRESSION; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

ANHEDONIA; DATABASES, BIBLIOGRAPHIC; DOPAMINE; DOPAMINE AGENTS; HUMANS; MENTAL DISORDERS; PARKINSON DISEASE;

EID: 80052258833     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23815     Document Type: Review

References (69)

1. Burns DJ. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. Mov Disord 2002; 17: 445-454.
2. Loas G. Anhedonia in major depression. Comparison of 55 depressed patients with 54 healthy probands. Encephale 1995; 21: 559-562.
3. Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 1991; 3: 243-254.
4. Kitanaka J, Kitanaka N, Takemura M. Neurochemical consequences of dysphoric state during amphetamine withdrawal in animal models: a review. Neurochem Res 2008; 33: 204-219.
5. Stevens A, Peschk I, Schwarz J. Implicit learning, executive function and hedonic activity in chronic polydrug abusers, currently abstinent polydrug abusers and controls. Addiction 2007; 102: 937-946.
6. Gard DE, Kring AM, Gard MG, Horan WP, Green MF. Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res 2007; 93: 253-260.
7. Harvey PO, Pruessner J, Czechowska Y, Lepage M. Individual differences in trait anhedonia: a structural and functional magnetic resonance imaging study in non-clinical subjects. Mol Psychiatry 2007; 12: 703, 767-775.
8. Heinz A, Schmidt LG, Reischies FM. Anhedonia in schizophrenic, depressed, or alcohol-dependent patients--neurobiological correlates. Pharmacopsychiatry 1994; 27(Suppl 1): 7-10.
9. Uhl GR, Hedreen JC, Price DL. Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology 1985; 35: 1215-1218.
10. Cantello R, Aguggia M, Gilli M, et al. Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse. J Neurol Neurosurg Psychiatry 1989; 52: 724-731.
11. Javoy-Agid F, Agid Y. Is the mesocortical dopaminergic system involved in Parkinson disease? Neurology 1980; 30: 1326-1330.
12. Kunig G, Leenders KL, Martin-Solch C, Missimer J, Magyar S, Schultz W. Reduced reward processing in the brains of Parkinsonian patients. Neuroreport 2000; 11: 3681-3687.
13. Braak H, Braak E. Pathoanatomy of Parkinson's disease. J Neurol 2000; 247(Suppl 2): II3-II10.
14. Fibiger HC. The neurobiological substrates of depression in Parkinson's disease: a hypothesis. Can J Neurol Sci 1984; 11(Suppl 1): 105-107.
15. Grafton ST. Contributions of functional imaging to understanding parkinsonian symptoms. Curr Opin Neurobiol 2004; 14: 715-719.
16. Malhi GS, Parker GB, Greenwood J. Structural and functional models of depression: from sub-types to substrates. Acta Psychiatr Scand 2005; 111: 94-105.
17. Pizzagalli DA, Oakes TR, Fox AS, et al. Functional but not structural subgenual prefrontal cortex abnormalities in melancholia. Mol Psychiatry 2004; 9: 325, 393-405.
18. Carey RJ. An examination of parkinsonian versus anhedonia contributions to self-stimulation impairments induced by dopamine dysfunction. Behav Brain Res 1986; 22: 117-125.
19. Ribot TH. The Psychology of Emotions. London; 1897.
20. APA. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington, DC; 1980.
21. WHO. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland; 1992.
22. APA. Diagnostic and Statistical Manual of Mental Disorders (IV-TR), 4th ed.-text revised. Washington, DC; 2000.
23. Chapman LJ, Chapman JP, Raulin ML. Scales for physical and social anhedonia. J Abnorm Psychol 1976; 85: 374-382.
24. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry 1995; 167: 99-103.
25. Fleminger S. Left-sided Parkinson's disease is associated with greater anxiety and depression. Psychol Med 1991; 21: 629-638.
26. Santangelo G, Vitale C, Trojano L, et al. Relationship between depression and cognitive dysfunctions in Parkinson's disease without dementia. J Neurol 2009a; 256: 632-638.
27. Pluck GC, Brown RG. Apathy in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002; 73: 636-642.
28. Reichmann H, Brecht MH, Koster J, Kraus PH, Lemke MR. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease. CNS Drugs 2003; 17: 965-973.
29. Isella V, Iurlaro S, Piolti R, et al. Physical anhedonia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003; 74: 1308-1311.
30. Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci 2005; 17: 214-220.
31. Lemke MR, Brecht HM, Koester J, Reichmann H. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J Neurol Sci 2006; 248: 266-270.
32. Weintraub D, Cary MS, Stern MB, Taraborelli D, Katz IR. Daily affect in Parkinson disease is responsive to life events and motor symptoms. Am J Geriatr Psychiatry 2006; 14: 161-168.
33. Witt K, Daniels C, Herzog J, et al. Differential effects of L-dopa and subthalamic stimulation on depressive symptoms and hedonic tone in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2006; 18: 397-401.
34. Reichmann H, Odin P, Brecht HM, Koster J, Kraus PH. Changing dopamine agonist treatment in Parkinson's disease: experiences with switching to pramipexole. J Neural Transm Suppl 2006; 71: 17-25.
35. Santangelo G, Morgante L, Savica R, et al. Anhedonia and cognitive impairment in Parkinson's disease: Italian validation of the Snaith-Hamilton Pleasure Scale and its application in the clinical routine practice during the PRIAMO study. Parkinsonism Relat Disord 2009b; 15: 576-581.
36. Task Force of the Movement Disorder Society. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002; 17(Suppl 4): S1-S166.
37. Martinez-Martin P, Deuschl G. Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease. Mov Disord 2007; 22: 757-765.
38. Snaith RP. Identifying depression: the significance of anhedonia. Hosp Pract (Off Ed) 1993; 28: 55-60.
39. Lemke MR, Puhl P, Koethe N, Winkler T. Psychomotor retardation and anhedonia in depression. Acta Psychiatr Scand 1999; 99: 252-256.
40. Taylor AE, Saint-Cyr JA. Depression in Parkinson's disease: reconciling physiological and psychological perspectives. J Neuropsychiatry Clin Neurosci 1990; 2: 92-98.
41. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571.
42. Wing JK, Cooper JE, Sartorius N. The Measurement and Classification of Psychiatric Symptoms. London; 1974.
43. Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 1991; 38: 143-162.
44. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370.
45. Rabkin JG, Ferrando SJ, van Gorp W, Rieppi R, McElhiney M, Sewell M. Relationships among apathy, depression, and cognitive impairment in HIV/AIDS. J Neuropsychiatry Clin Neurosci 2000; 12: 451-457.
46. Rabey JM, Bass H, Bonuccelli U, et al. Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials. Clin Neuropharmacol 1997; 20: 322-337.
47. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
48. Royall DR, Mahurin RK, Gray KF. Bedside assessment of executive cognitive impairment: the executive interview. J Am Geriatr Soc 1992; 40: 1221-1226.
49. APA. Diagnostic and statistical manual of mental disorder, 4th ed. Washington, DC; 1994.
50. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology 2000; 55: 1621-1626.
51. Caltagirone C, Gainotti G, Masullo C, Miceli G. Validity of some neuropsychological tests in the assessment of mental deterioration. Acta Psychiatr Scand 1979; 60: 50-56.
52. Spinnler H, Tognoni G. Standardizzazione e taratura italiana di una batteria di test neuropicologici. Ital J Neurol Sci 1987; (Suppl 8): 78-80; 97-99.
53. Barbarotto R, Laiacona M, Frosio R, Vecchio M, Farinato A, Capitani E. A normative study on visual reaction times and two Stroop colour-word tests. Ital J Neurol Sci 1998; 19(3): 161-170.
54. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
55. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8: 464-474.
56. Wise RA, Spindler J, deWit H, Gerberg GJ. Neuroleptic-induced "anhedonia" in rats: pimozide blocks reward quality of food. Science 1978; 201: 262-264.
57. Voruganti L, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl) 2004; 171: 121-132.
58. Scharfetter C. General Psychopathology: An Introduction. Cambridge, UK: Cambridge University Press; 1980.
59. Lemke MR. Depressive symptoms in Parkinson's disease. Eur J Neurol 2008; 15(Suppl 1): 21-25.
60. Keedwell PA, Andrew C, Williams SC, Brammer MJ, Phillips ML. The neural correlates of anhedonia in major depressive disorder. Biol Psychiatry 2005; 58: 843-853.
61. Pizzagalli DA, Holmes AJ, Dillon DG, et al. Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am J Psychiatry 2009; 166: 702-710.
62. Demyttenaere K, De Fruyt J, Stahl SM. The many faces of fatigue in major depressive disorder. Int J Neuropsychopharmacol 2005; 8: 93-105.
63. Schrijvers D, Hulstijn W, Sabbe BG. Psychomotor symptoms in depression: a diagnostic, pathophysiological and therapeutic tool. J Affect Disord 2008; 109: 1-20.
64. Stein DJ. Depression, anhedonia, and psychomotor symptoms: the role of dopaminergic neurocircuitry. CNS Spectr 2008; 13: 561-565.
65. Bressan RA, Crippa JA. The role of dopamine in reward and pleasure behaviour--review of data from preclinical research. Acta Psychiatr Scand Suppl 2005; 427: 14-21.
66. Winograd-Gurvich C, Fitzgerald PB, Georgiou-Karistianis N, Bradshaw JL, White OB. Negative symptoms: a review of schizophrenia, melancholic depression and Parkinson's disease. Brain Res Bull 2006; 70: 312-321.
67. Nakamura K, Matsumoto M, Hikosaka O. Reward-dependent modulation of neuronal activity in the primate dorsal raphe nucleus. J Neurosci 2008; 28: 5331-5343.
68. Kranz GS, Kasper S, Lanzenberger R. Reward and the serotonergic system. Neuroscience 2010; 166: 1023-1035.
69. Leentjens AF, Dujardin K, Marsh L, et al. Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2008; 23: 2004-2014.